Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review

Sarah B. Doernberg; Cesar A. Arias; Deena R. Altman; Ahmed Babiker; Helen W. Boucher; C. Buddy Creech; Sara E. Cosgrove; Scott R. Evans; Vance G. Fowler; Stephanie A. Fritz; Toshimitsu Hamasaki; Brendan J. Kelly; Sixto M. Leal; Catherine Liu; Thomas P. Lodise; Loren G. Miller; Jose M. Munita; Barbara E. Murray; Melinda M. Pettigrew; Felicia Ruffin; Marc H. Scheetz; Bo Shopsin; Truc T. Tran; Nicholas A. Turner; Derek J. Williams; Smitha Zaharoff; Thomas L. Holland

doi:10.1093/cid/ciad565

Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review

Sarah B. Doernberg, Cesar A. Arias, Deena R. Altman, Ahmed Babiker, Helen W. Boucher, C. Buddy Creech, Sara E. Cosgrove, Scott R. Evans, Vance G. Fowler, Stephanie A. Fritz, Toshimitsu Hamasaki, Brendan J. Kelly, Sixto M. Leal, Catherine Liu, Thomas P. Lodise, Loren G. Miller, Jose M. Munita, Barbara E. Murray, Melinda M. Pettigrew, Felicia RuffinMarc H. Scheetz, Bo Shopsin, Truc T. Tran, Nicholas A. Turner, Derek J. Williams, Smitha Zaharoff, Thomas L. Holland

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

The Antibacterial Resistance Leadership Group (ARLG) has prioritized infections caused by gram-positive bacteria as one of its core areas of emphasis. The ARLG Gram-positive Committee has focused on studies responding to 3 main identified research priorities: (1) investigation of strategies or therapies for infections predominantly caused by gram-positive bacteria, (2) evaluation of the efficacy of novel agents for infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci, and (3) optimization of dosing and duration of antimicrobial agents for gram-positive infections. Herein, we summarize ARLG accomplishments in gram-positive bacterial infection research, including studies aiming to (1) inform optimal vancomycin dosing, (2) determine the role of dalbavancin in MRSA bloodstream infection, (3) characterize enterococcal bloodstream infections, (4) demonstrate the benefits of short-course therapy for pediatric community-acquired pneumonia, (5) develop quality of life measures for use in clinical trials, and (6) advance understanding of the microbiome. Future studies will incorporate innovative methodologies with a focus on interventional clinical trials that have the potential to change clinical practice for difficult-to-treat infections, such as MRSA bloodstream infections.

Original language	English
Pages (from-to)	S295-S304
Journal	Clinical Infectious Diseases
Volume	77
DOIs	https://doi.org/10.1093/cid/ciad565
State	Published - Oct 15 2023

Keywords

antibacterial agents
antibacterial resistance
gram-positive bacterial infections
methicillin-resistant Staphylococcus aureus
vancomycin-resistant enterococci

Access to Document

10.1093/cid/ciad565

Cite this

Doernberg, S. B., Arias, C. A., Altman, D. R., Babiker, A., Boucher, H. W., Buddy Creech, C., Cosgrove, S. E., Evans, S. R., Fowler, V. G., Fritz, S. A., Hamasaki, T., Kelly, B. J., Leal, S. M., Liu, C., Lodise, T. P., Miller, L. G., Munita, J. M., Murray, B. E., Pettigrew, M. M., ... Holland, T. L. (2023). Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review. Clinical Infectious Diseases, 77, S295-S304. https://doi.org/10.1093/cid/ciad565

@article{aae5c3d9c8bf45d2a6c067576330f987,

title = "Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review",

abstract = "The Antibacterial Resistance Leadership Group (ARLG) has prioritized infections caused by gram-positive bacteria as one of its core areas of emphasis. The ARLG Gram-positive Committee has focused on studies responding to 3 main identified research priorities: (1) investigation of strategies or therapies for infections predominantly caused by gram-positive bacteria, (2) evaluation of the efficacy of novel agents for infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci, and (3) optimization of dosing and duration of antimicrobial agents for gram-positive infections. Herein, we summarize ARLG accomplishments in gram-positive bacterial infection research, including studies aiming to (1) inform optimal vancomycin dosing, (2) determine the role of dalbavancin in MRSA bloodstream infection, (3) characterize enterococcal bloodstream infections, (4) demonstrate the benefits of short-course therapy for pediatric community-acquired pneumonia, (5) develop quality of life measures for use in clinical trials, and (6) advance understanding of the microbiome. Future studies will incorporate innovative methodologies with a focus on interventional clinical trials that have the potential to change clinical practice for difficult-to-treat infections, such as MRSA bloodstream infections.",

keywords = "antibacterial agents, antibacterial resistance, gram-positive bacterial infections, methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci",

author = "Doernberg, {Sarah B.} and Arias, {Cesar A.} and Altman, {Deena R.} and Ahmed Babiker and Boucher, {Helen W.} and {Buddy Creech}, C. and Cosgrove, {Sara E.} and Evans, {Scott R.} and Fowler, {Vance G.} and Fritz, {Stephanie A.} and Toshimitsu Hamasaki and Kelly, {Brendan J.} and Leal, {Sixto M.} and Catherine Liu and Lodise, {Thomas P.} and Miller, {Loren G.} and Munita, {Jose M.} and Murray, {Barbara E.} and Pettigrew, {Melinda M.} and Felicia Ruffin and Scheetz, {Marc H.} and Bo Shopsin and Tran, {Truc T.} and Turner, {Nicholas A.} and Williams, {Derek J.} and Smitha Zaharoff and Holland, {Thomas L.}",

year = "2023",

month = oct,

day = "15",

doi = "10.1093/cid/ciad565",

language = "English",

volume = "77",

pages = "S295--S304",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

}

Doernberg, SB, Arias, CA, Altman, DR, Babiker, A, Boucher, HW, Buddy Creech, C, Cosgrove, SE, Evans, SR, Fowler, VG, Fritz, SA, Hamasaki, T, Kelly, BJ, Leal, SM, Liu, C, Lodise, TP, Miller, LG, Munita, JM, Murray, BE, Pettigrew, MM, Ruffin, F, Scheetz, MH, Shopsin, B, Tran, TT, Turner, NA, Williams, DJ, Zaharoff, S & Holland, TL 2023, 'Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review', Clinical Infectious Diseases, vol. 77, pp. S295-S304. https://doi.org/10.1093/cid/ciad565

TY - JOUR

T1 - Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group

T2 - A Narrative Review

AU - Doernberg, Sarah B.

AU - Arias, Cesar A.

AU - Altman, Deena R.

AU - Babiker, Ahmed

AU - Boucher, Helen W.

AU - Buddy Creech, C.

AU - Cosgrove, Sara E.

AU - Evans, Scott R.

AU - Fowler, Vance G.

AU - Fritz, Stephanie A.

AU - Hamasaki, Toshimitsu

AU - Kelly, Brendan J.

AU - Leal, Sixto M.

AU - Liu, Catherine

AU - Lodise, Thomas P.

AU - Miller, Loren G.

AU - Munita, Jose M.

AU - Murray, Barbara E.

AU - Pettigrew, Melinda M.

AU - Ruffin, Felicia

AU - Scheetz, Marc H.

AU - Shopsin, Bo

AU - Tran, Truc T.

AU - Turner, Nicholas A.

AU - Williams, Derek J.

AU - Zaharoff, Smitha

AU - Holland, Thomas L.

PY - 2023/10/15

Y1 - 2023/10/15

N2 - The Antibacterial Resistance Leadership Group (ARLG) has prioritized infections caused by gram-positive bacteria as one of its core areas of emphasis. The ARLG Gram-positive Committee has focused on studies responding to 3 main identified research priorities: (1) investigation of strategies or therapies for infections predominantly caused by gram-positive bacteria, (2) evaluation of the efficacy of novel agents for infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci, and (3) optimization of dosing and duration of antimicrobial agents for gram-positive infections. Herein, we summarize ARLG accomplishments in gram-positive bacterial infection research, including studies aiming to (1) inform optimal vancomycin dosing, (2) determine the role of dalbavancin in MRSA bloodstream infection, (3) characterize enterococcal bloodstream infections, (4) demonstrate the benefits of short-course therapy for pediatric community-acquired pneumonia, (5) develop quality of life measures for use in clinical trials, and (6) advance understanding of the microbiome. Future studies will incorporate innovative methodologies with a focus on interventional clinical trials that have the potential to change clinical practice for difficult-to-treat infections, such as MRSA bloodstream infections.

AB - The Antibacterial Resistance Leadership Group (ARLG) has prioritized infections caused by gram-positive bacteria as one of its core areas of emphasis. The ARLG Gram-positive Committee has focused on studies responding to 3 main identified research priorities: (1) investigation of strategies or therapies for infections predominantly caused by gram-positive bacteria, (2) evaluation of the efficacy of novel agents for infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci, and (3) optimization of dosing and duration of antimicrobial agents for gram-positive infections. Herein, we summarize ARLG accomplishments in gram-positive bacterial infection research, including studies aiming to (1) inform optimal vancomycin dosing, (2) determine the role of dalbavancin in MRSA bloodstream infection, (3) characterize enterococcal bloodstream infections, (4) demonstrate the benefits of short-course therapy for pediatric community-acquired pneumonia, (5) develop quality of life measures for use in clinical trials, and (6) advance understanding of the microbiome. Future studies will incorporate innovative methodologies with a focus on interventional clinical trials that have the potential to change clinical practice for difficult-to-treat infections, such as MRSA bloodstream infections.

KW - antibacterial agents

KW - antibacterial resistance

KW - gram-positive bacterial infections

KW - methicillin-resistant Staphylococcus aureus

KW - vancomycin-resistant enterococci

UR - http://www.scopus.com/inward/record.url?scp=85174750573&partnerID=8YFLogxK

U2 - 10.1093/cid/ciad565

DO - 10.1093/cid/ciad565

M3 - Article

C2 - 37843115

AN - SCOPUS:85174750573

SN - 1058-4838

VL - 77

SP - S295-S304

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

ER -

Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this